Background Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11.
Methods Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period.
Results Both ligands displayed highly significant group discrimination and correlation of regional uptake.
Conclusion These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.
- Alzheimer's disease
- event-related potentials
Statistics from Altmetric.com
Funding This study was supported in its entirety by the Pennsylvania Department of Health (#4100037703).
Competing interests Dr Wolk has received consulting fees from GE Healthcare, Inc. Drs Clark and Pontecorvo owned Avid stock and/or stock options and are employed by Avid Radiopharmaceuticals Inc, a wholly owned subsidiary of Eli Lilly and Company.
Ethics approval Ethics approval was provided by University of Pennsylvania Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.